The role of fluorine-18-fluorodeoxyglucose positron emission tomography in evaluating the response to tyrosine-kinase inhibitors in patients with metastatic primary renal cell carcinoma

1. Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr. Rising incidence of renal cell cancer in the United States. JAMA 1999; 281: 1628-31.10.1001/jama.281.17.162810235157Search in Google Scholar

2. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: cancer incidence, mortality, and prevalence worldwide. Lyon: IARC Press. http://www-dep. iarc.fr/. Accessed 10 October 2012.Search in Google Scholar

3. Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol 2010; 7: 245-57.10.1038/nrurol.2010.46301245520448658Search in Google Scholar

4. Weikert S, Ljungberg B. Contemporary epidemiology of renal cell carcinoma: perspectives of primary prevention. World J Urol 2010; 28: 247-52.10.1007/s00345-010-0555-120390283Search in Google Scholar

5. Klatte T, Pantuck AJ, Kleid MD, Belldegrun AS. Understanding the natural biology of kidney cancer: implications for targeted cancer therapy. Rev Urol 2007; 9: 47-56.Search in Google Scholar

6. Bukowski RM. Prognostic factors for survival in metastatic renal cell carcinoma: update 2008. Cancer 2009; 115: 2273-81.10.1002/cncr.2422619402065Search in Google Scholar

7. Cruz A, Ramírez LM, Sánchez E, Ruiz M, Moreno I, López J, et al. Gastric metastasis from renal cancer six years after nephrectomy. Rev Esp Enferm Dig 2011; 103: 660-1.10.4321/S1130-01082011001200014Search in Google Scholar

8. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996; 335: 865-75.10.1056/NEJM1996091933512078778606Search in Google Scholar

9. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17: 2530-40.10.1200/JCO.1999.17.8.253010561319Search in Google Scholar

10. Castellano D, del Muro XG, Pérez-Gracia JL, González-Larriba JL, Abrio MV, Ruiz MA, et al. Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-{alpha} as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population. Ann Oncol 2009; 20: 1803-12.10.1093/annonc/mdp067276873419549706Search in Google Scholar

11. Cella D, Michaelson MD, Bushmakin AG, Cappelleri JC, Charbonneau C, Kim ST, et al. Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase III trial: final results and geographical analysis. Br J Cancer 2010; 102: 658-64.10.1038/sj.bjc.6605552283756720104222Search in Google Scholar

12. Jonasch E, Corn P, Pagliaro LC, Warneke CL, Johnson MM, Tamboli P, et al. Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and lowdose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer 2010; 116: 57-65.Search in Google Scholar

13. Procopio G, Verzoni E, Bracarda S, Ricci S, Sacco C, Ridolfi L, et al. Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial. Br J Cancer 2011; 104: 1256-61.10.1038/bjc.2011.103307858921448165Search in Google Scholar

14. Jadvar H, Kherbache HM, Pinski JK, Conti PS. Diagnostic role of [F-18]- FDG positron emission tomography in restaging renal cell carcinoma. Clin Nephrol 2003; 60: 395-400.10.5414/CNP60395Search in Google Scholar

15. Powles T, Murray I, Brock C, Oliver T, Avril N. Molecular positron emission tomography and PET/CT imaging in urological malignancies. Eur Urol 2007; 51: 1511-20.10.1016/j.eururo.2007.01.06117275167Search in Google Scholar

16. Wang HY, Ding HJ, Chen JH, Chao CH, Lu YY, Lin WY, et al. Meta-analysis of the diagnostic performance of [18F]FDG-PET and PET/CT in renal cell carcinoma. Cancer Imaging 2012: 12: 464-74.10.1102/1470-7330.2012.0042348359923108238Search in Google Scholar

17. Whiting PF, Weswood ME, Rutjes AW, Reitsma JB, Bossuyt PN, Kleijnen J. Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Methodol 2006; 6: 9.10.1186/1471-2288-6-9142142216519814Search in Google Scholar

18. Khandani AH, Cowey CL, Moore DT, Gohil H, Rathmell WK. Primary renal cell carcinoma: relationship between 18F-FDG uptake and response to neoadjuvant sorafenib. Nucl Med Commun 2012; 33: 967-73.10.1097/MNM.0b013e328356183722714005Search in Google Scholar

19. Lyrdal D, Boijsen M, Suurküla M, Lundstam S, Stierner U. Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography. Nucl Med Commun 2009; 30: 519-24.10.1097/MNM.0b013e32832cc220Search in Google Scholar

20. Ueno D, Yao M, Tateishi U, Minamimoto R, Makiyama K, Hayashi N, et al. Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course. BMC Cancer 2012; 12: 162.10.1186/1471-2407-12-162341856622551397Search in Google Scholar

21. Vaishampayan UN, Heilbrun LK, Shields AF, Lawhorn-Crews J, Baranowski K, Smith D, et al. Phase II trial of interferon and thalidomide in metastatic renal cell carcinoma. Invest New Drugs 2007; 25: 69-75.10.1007/s10637-006-9005-816937078Search in Google Scholar

22. Vercellino L, Bousquet G, Baillet G, Barré E, Mathieu O, Just PA, et al. 18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study. Cancer Biother Radiopharm 2009; 24: 137-44.10.1089/cbr.2008.052719243256Search in Google Scholar

23. Kayani I, Avril N, Bomanji J, Chowdhury S, Rockall A, Sahdev A, et al. Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer. Clin Cancer Res 2011; 17: 6021-8.10.1158/1078-0432.CCR-10-330921742806Search in Google Scholar

24. Minamimoto R, Nakaigawa N, Tateishi U, Suzuki A, Shizukuishi K, Kishida T, et al. Evaluation of response to multikinase inhibitor in metastatic renal cell carcinoma by FDG PET/contrast-enhanced CT. Clin Nucl Med 2010; 35: 918-23.10.1097/RLU.0b013e3181f9ddd9Search in Google Scholar

25. Revheim ME, Winge-Main AK, Hagen G, Fjeld JG, Fosså SD, Lilleby W. Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma. Clin Oncol (R Coll Radiol) 2011; 23: 339-43.10.1016/j.clon.2010.11.006Search in Google Scholar

26. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999; 35: 1773-82.10.1016/S0959-8049(99)00229-4Search in Google Scholar

27. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.10.1093/jnci/92.3.205Search in Google Scholar

28. Stroobants S, Goeminne J, Seegers M, Dimitrijevic S, Dupont P, Nuyts J, et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 2003; 39: 2012-20.10.1016/S0959-8049(03)00073-XSearch in Google Scholar

29. Atzpodien J, Schmitt E, Gertenbach U, Fornara P, Heynemann H, Maskow A, et al. Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer 2005; 92: 843-6.10.1038/sj.bjc.6602443236191515756254Search in Google Scholar

30. Bex A, Mallo H, Kerst M, Haanen J, Horenblas S, de Gast GC. A phase-II study of pegylated interferon alfa-2b for patients with metastatic renal cell carcinoma and removal of the primary tumor. Cancer Immunol Immunother 2005; 54: 713-9.10.1007/s00262-004-0630-915627213Search in Google Scholar

31. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-81.10.1056/NEJMoa06683817538086Search in Google Scholar

32. Segota E, Mekhail T, Olencki T, Hutson TE, Dreicer R, Wacker B, et al. Phase II trial of capecitabine and rHu-interferon-alpha-2a in patients with metastatic renal cell carcinoma, limited efficacy, and moderate toxicity. Urol Oncol 2007; 25: 46-52.10.1016/j.urolonc.2006.02.01617208138Search in Google Scholar

33. Ambring A, Björholt I, Lesén E, Stierner U, Odén A. Treatment with sorafenib and sunitinib in renal cell cancer: a Swedish register-based study. Med Oncol 2013; 30: 331.10.1007/s12032-012-0331-8358640023254966Search in Google Scholar

34. Eichelberg C, Heuer R, Chun FK, Hinrichs K, Zacharias M, Huland H, et al. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur Urol 2008; 54: 1373-8. 10.1016/j.eururo.2008.07.05118692304Search in Google Scholar